People · Operator
Named in public records as an officer, director or promoter · active 2018–2018 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Velicept Therapeutics, Inc. | — | Pharmaceuticals | Series B | $39.9M | $204.0M | 2018 |
Cory Freedman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Cory Freedman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James Walker | 1 | 16 |
| David Hirsch | 1 | 16 |
| Stephen Tullman | 1 | 7 |
| Douglas Gessl | 1 | 4 |
| James C. Walker | 1 | 3 |
| Aidan King | 1 | 3 |
| Scott S. Morenstein | 1 | 3 |
| Scott Morenstein | 1 | 2 |
| Cory S. Freedland | 1 | 1 |
| Doug Becker Gessl | 1 | 1 |
| David Becker Hirsch, M.D. | 1 | 1 |
| Jill Becker Mast | 1 | 1 |
| Stephen S. Tullman | 1 | 1 |
| James Bennethum | 1 | 1 |
| Aidan S. King, MBA, CFA | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.